According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
